Cell and Gene Therapy CDMO Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell and Gene Therapy CDMO Market 

5.1. COVID-19 Landscape: Cell and Gene Therapy CDMO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell and Gene Therapy CDMO Market, By Type of Therapy

8.1. Cell and Gene Therapy CDMO Market, by Type of Therapy

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Cell Therapy

8.1.2.1. Market Revenue and Forecast

8.1.3. Stem Cell Therapy

8.1.3.1. Market Revenue and Forecast

8.1.4. CAR-T Therapy

8.1.4.1. Market Revenue and Forecast

8.1.4. Other Cell Therapies

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Cell and Gene Therapy CDMO Market, By Type of Manufacturing Service

9.1. Cell and Gene Therapy CDMO Market, by Type of Manufacturing Service

9.1.1. Development Services

9.1.1.1. Market Revenue and Forecast

9.1.2. Manufacturing Services

9.1.2.1. Market Revenue and Forecast

9.1.3. Other Services

Chapter 10. Global Cell and Gene Therapy CDMO Market, By Cell and Gene Therapy Modality

10.1. Cell and Gene Therapy CDMO Market, by Technology

10.1.1. Viral Vectors

10.1.1.1. Market Revenue and Forecast

10.1.2. Non-Viral Vectors

10.1.2.1. Market Revenue and Forecast

10.1.3. CRISPR/Cas9 and Other Gene Editing Tools

Chapter 11. Global Cell and Gene Therapy CDMO Market, By Therapeutic Area

11.1. Cell and Gene Therapy CDMO Market, by Therapeutic Area

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast

11.1.2. Neurology

11.1.2.1. Market Revenue and Forecast

11.1.3. Cardiovascular

11.1.3.1. Market Revenue and Forecast

11.1.4. Metabolic Disorders

11.1.4.1. Market Revenue and Forecast

11.1.5. Other Therapeutic Areas

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global Cell and Gene Therapy CDMO Market, By End-User

12.1. Cell and Gene Therapy CDMO Market, by End-User

12.1.1. Biopharmaceutical Companies

12.1.1.1. Market Revenue and Forecast

12.1.2. Biopharmaceutical Companies

12.1.2.1. Market Revenue and Forecast

12.1.3. Contract Development & Manufacturing Organizations (CDMOs)

12.1.3.1. Market Revenue and Forecast

Chapter 13. Global Cell and Gene Therapy CDMO Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type of Therapy

13.1.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.1.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.1.4. Market Revenue and Forecast, by Therapeutic Area

13.1.5. Market Revenue and Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type of Therapy

13.1.6.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.1.6.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.1.6.4. Market Revenue and Forecast, by Therapeutic Area

13.1.6.5. Market Revenue and Forecast, by End-User

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Type of Therapy

13.1.7.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.1.7.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.1.7.4. Market Revenue and Forecast, by Therapeutic Area

13.1.7.5. Market Revenue and Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type of Therapy

13.2.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.2.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.2.4. Market Revenue and Forecast, by Therapeutic Area  

13.2.5. Market Revenue and Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type of Therapy

13.2.6.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.2.6.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.2.7. Market Revenue and Forecast, by Therapeutic Area  

13.2.8. Market Revenue and Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type of Therapy

13.2.9.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.2.9.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.2.10. Market Revenue and Forecast, by Therapeutic Area

13.2.11. Market Revenue and Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type of Therapy

13.2.12.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.2.12.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.2.12.4. Market Revenue and Forecast, by Therapeutic Area

13.2.13. Market Revenue and Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type of Therapy

13.2.14.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.2.14.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.2.14.4. Market Revenue and Forecast, by Therapeutic Area

13.2.15. Market Revenue and Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type of Therapy

13.3.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.3.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.3.4. Market Revenue and Forecast, by Therapeutic Area

13.3.5. Market Revenue and Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type of Therapy

13.3.6.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.3.6.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.3.6.4. Market Revenue and Forecast, by Therapeutic Area

13.3.7. Market Revenue and Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type of Therapy

13.3.8.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.3.8.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.3.8.4. Market Revenue and Forecast, by Therapeutic Area

13.3.9. Market Revenue and Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type of Therapy

13.3.10.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.3.10.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.3.10.4. Market Revenue and Forecast, by Therapeutic Area

13.3.10.5. Market Revenue and Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type of Therapy

13.3.11.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.3.11.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.3.11.4. Market Revenue and Forecast, by Therapeutic Area

13.3.11.5. Market Revenue and Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type of Therapy

13.4.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.4.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.4.4. Market Revenue and Forecast, by Therapeutic Area

13.4.5. Market Revenue and Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type of Therapy

13.4.6.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.4.6.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.4.6.4. Market Revenue and Forecast, by Therapeutic Area

13.4.7. Market Revenue and Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type of Therapy

13.4.8.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.4.8.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.4.8.4. Market Revenue and Forecast, by Therapeutic Area

13.4.9. Market Revenue and Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type of Therapy

13.4.10.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.4.10.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.4.10.4. Market Revenue and Forecast, by Therapeutic Area

13.4.10.5. Market Revenue and Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type of Therapy

13.4.11.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.4.11.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.4.11.4. Market Revenue and Forecast, by Therapeutic Area

13.4.11.5. Market Revenue and Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type of Therapy

13.5.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.5.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.5.4. Market Revenue and Forecast, by Therapeutic Area

13.5.5. Market Revenue and Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type of Therapy

13.5.6.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.5.6.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.5.6.4. Market Revenue and Forecast, by Therapeutic Area

13.5.7. Market Revenue and Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type of Therapy

13.5.8.2. Market Revenue and Forecast, by Type of Manufacturing Service

13.5.8.3. Market Revenue and Forecast, by Cell and Gene Therapy Modality

13.5.8.4. Market Revenue and Forecast, by Therapeutic Area

13.5.8.5. Market Revenue and Forecast, by End-User

Chapter 14. Company Profiles

14.1.  Avid Bioservices

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Catalent

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Catalent

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Curia

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Emergent BioSolutions

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Eurofins

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. FUJIFILM Diosynth Biotechnologies

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Genscript

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Lonza

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Pfizer CentreOne

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms